The China National Intellectual Property Administration CNIPA announced the following...

Some recent updates from China as below on company names, abnormal patent applications, and green technologies...

This is the law in China mainly protecting trade secrets and unregistered trademarks. After the last draft in December 2024, which the Intellectual Property Owners Association (IPO) provided comments on, the final version was announced on 27 June 2025 at the link below:

The new Chinese Trademark Law 2026 will become effective on 1 January 2027. In response to this, the CNIPA announced the following drafts on 28 September 2026 for comments:

On 3 August 2021, the CNIPA published yet another draft revisions to the CN Patent Examination Guidelines (the Guidelines).

Supply of generic drugs and their interaction with the patent system, like standards essential patents, present one of the international frontiers of patent protection.

Thanks to the heads up from Aaron Wininger , on 19 March 2025, the China National Medical Products Administration (NMPA) announced the draft Implementation Measures for Drug Trial Data Protection (IM), and their procedures.

There are six cases that are IP related as below (AM means anti-monopoly case, while AU means anti-unfair competition case...

CN SAMR announced 4 anti-monopoly related regulations, all on 10 Mar 2023, and will come into force on 15 April 2023...

On 1 December 2023, the CNIPA provided the above draft at the following link, with deadline to comment being on 31 December 2023..

Major improvements are on design patent, and patent infringement compensation.

The deadline to submit comments is 22 Sep 2021. This was just announced earlier today (3 Aug 2021)...

With the information from Chenghua Luo of Amgen , which is highly appreciated, I write to report on the first drug patent term extension (DPTE) granted in China. Please correct me if anyone is aware of another DPTE granted in China earlier.

China has a doctrine of "equivalence" – it may be the patentee's last hope. While the statistics for decisions in Europe, the US, and Japan show that it is not easy to sue successfully for patent infringement...

Thanks for the heads-up from Aaron Wininger of Schwegman Lundberg & Woessner, P.A. , the China National People's Congress has announced the most recent draft Chinese Trademark Law revision on 27 December 2025 at the link below as the New Year present, setting the deadline comment to be 9 February 2026:

As reported in my previous article (see below), the Chinese Patent Examination Guidelines 2023 was announced by the CNIPA on 21 December 2023 ...

Thanks again for the heads up from Aaron Wininger of Schwegman Lundberg & Woessner, the China Supreme Court (the Supreme Court) has decided on the appeal of this first drug patent linkage decision, which is final.

The deadline to provide comments for this 30-pages document with 54 articles is 23 August 2024, that is within 14 days from the announcement.

This Method is drafted by China's National Medical Products Administration in conjunction with the China National IP Administration, and was published for public's comments on 11 September 2020 in the link below.

On 3 July 2020, the Chinese National People's Congress (NPC) published the second deliberation draft of the fourth amendments to the Chinese Patent Law (the fourth amendments).